TY  - JOUR 
AU  - Carrato, A
AU  - Benavides, M
AU  - Massuti, B
AU  - Ferreiro-Monteagudo, R
AU  - Garcia Alfonso, P
AU  - Falco, E
AU  - Reboredo Lopez, Margarita
AU  - Cano, T
AU  - Gallego, J
AU  - Vieitez, J M
AU  - Layos, L
AU  - Salud, A
AU  - Polo, E
AU  - Dotor, E
AU  - Duran-Ogalla, G
AU  - Rodriguez-Garrote, M
AU  - Calvo, A
AU  - Grande, E
AU  - Aranda, E
PY  - 2019
SN  - 1471-2407
UR  - http://hdl.handle.net/20.500.11940/15934
AB  - BACKGROUND: Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC....
LA  - eng
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Hypophosphatemia
KW  - Follow-Up Studies
KW  - Pyridines
KW  - Humans
KW  - Treatment Outcome
KW  - Pilot Projects
KW  - Asthenia
KW  - Aged
KW  - Hypertension
KW  - Colorectal Neoplasms
KW  - Phenylurea Compounds
TI  - First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
DO  - 10.1186/s12885-019-5753-7
T2  - BMC CANCER
KW  - CHUAC
VL  - 19
ER  -